FDA approves twice-a-year injection for HIV prevention
Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo. In clinical trials, the drug was found to dramatically reduce the risk of infection and provide near-total protection against HIV, significantly more than the primary options available for pre-exposure prophylaxis or PrEP.
Therapies called PrEP have been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting shots, such as injections every two months of the medication Apretude. But a twice-yearly shot of lenacapavir has now become another option in the prevention toolbox – making it the first and only such shot for HIV prevention.
'Yeztugo could be the transformative PrEP option we've been waiting for – offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,' Dr. Carlos del Rio, a distinguished professor of medicine in the Division of Infectious Diseases at Emory University School of Medicine and co-director of the Emory Center for AIDS Research, said in a Gilead news release. 'A twice-yearly injection could greatly address key barriers like adherence and stigma, which individuals on more frequent PrEP dosing regimens, especially daily oral PrEP, can face. We also know that, in research, many people who need or want PrEP preferred less frequent dosing.'
With any PrEP drug, 'by having that medicine in your bloodstream or in your body, if you encounter HIV, it blocks it from taking hold. It arrests infection from taking hold,' said Dr. Jared Baeten, senior vice president of clinical development and the virology therapeutic area head at Gilead Sciences.
The human immunodeficiency virus or HIV, spread primarily through unprotected sex or sharing needles, attacks the body's immune system, and without treatment, it can lead to acquired immunodeficiency syndrome or AIDS. Although rates of new HIV infections have fallen in the US, about 1.2 million people are estimated to have HIV, and about 13% of them may not know it.
A study called the PURPOSE 2 trial found that just two shots a year of lenacapavir can reduce the risk of HIV infection by 96%, proving it to offer near-total protection against HIV. Another study, the PURPOSE 1 trial, found that lenacapavir demonstrated 100% efficacy for HIV prevention in women.
'Lenacapavir is a unique option for people for HIV prevention because it's an injection given just twice a year. So people can get it privately, discreetly, and then set it and forget it and not have to think about it until six months later,' Baeten said. 'For many people, that might be the empowered, private option that might make HIV prevention workable in their lives.'
There continues to be a lot of stigma, fear and misinformation around HIV, said Ian Haddock, who participated in the PURPOSE 2 trial for lenacapavir.
When Haddock was a teenager living in rural Texas, he recalled, he faced some of that stigma.
'The first thing that was said when my family found out that I was queer was, 'You're going to get AIDS,' ' said Haddock, who does not live with HIV. 'So that's the first thing I heard.'
Now, at 37, Haddock knows that HIV does not discriminate. He works to break such misguided stereotypes about the LGBTQ+ community as the founder of a nonprofit called the Normal Anomaly Initiative, and he said he is proud to have participated in the clinical trial.
'It feels like a full-circle moment,' he said.
Haddock said he started to take daily PrEP pills in 2015 to help reduce his risk of HIV, but sometimes they would give him an upset stomach or he would forget to take them.
In January 2024, when he learned about the lenacapavir clinical trial, he quickly enrolled. He had no side effects during the trial other than irritation at the injection site, he said.
Even though the trial has concluded, Haddock said, he plans to continue receiving lenacapavir injections twice a year, and he hopes the FDA approval will help raise awareness of HIV prevention tools.
In 2012, the FDA approved Truvada, also made by Gilead Sciences, making it the first PrEP medication for HIV prevention in uninfected adults in the United States – but 'even though PrEP has been around since 2012, people don't really know what it is, and they often kind of conflate it to having HIV or being extremely promiscuous,' Haddock said.
'So this just opens up a completely new opportunity,' he said of lenacapavir.
Last year, Gilead Sciences released data from the PURPOSE 2 trial that showed 99.9% of the participants who received an injection of lenacapavir twice a year for HIV prevention did not become infected.
There were only two cases among 2,180 people, effectively proving 89% more effective than the PrEP pill Truvada. The trial was unblinded early because it met its key endpoints, allowing lenacapavir to be offered to all participants, and the drug was found to be well-tolerated.
'The most common side effects, as you might expect, are injection-site reactions,' Baeten said, such as rash or discomfort.
The PURPOSE 2 trial included cisgender men, transgender men, transgender women and nonbinary people 16 or older who had sex with partners assigned male at birth. Some of the study participants became pregnant during the trial and continued to receive lenacapavir during pregnancy without complications, Baeten said.
'This is a milestone moment in the decades-long fight against HIV. With twice-yearly administration and remarkable efficacy, lenacapavir will help us prevent HIV on a scale never seen before,' Daniel O'Day, chairman and chief executive officer at Gilead Sciences, said in an emailed statement.
'After 17 years of research and pioneering clinical trials, Gilead scientists have delivered the next frontier in HIV innovation: a prevention medicine with remarkable efficacy that only needs to be delivered twice a year,' O'Day said. 'It's a true scientific breakthrough that could help millions of people around the world.'
Now that lenacapavir has been approved for prevention, people should be able to visit their providers and ask about the drug within two days, Gilead Sciences said in an email. The company added that it could take up to two months for someone to receive their first injections, based on coverage decisions.
The list price for lenacapavir, when used for HIV prevention, will be announced soon, Baeten said. The list price is expected to be different from when lenacapavir is used for the treatment of multidrug-resistant HIV, in which other HIV medications have not worked and the patient meets certain other requirements for lenacapavir treatment.
One study published in November in the Journal of Antimicrobial Chemotherapy found that for treatment, lenacapavir costs up to nearly $45,000 per person per year without insurance, as an average wholesale list price – but it could be mass-produced for less than $100 per person per year.
The team of researchers behind the study projected a possible minimum price based on the drug's current ingredients, production models and cost models. They demonstrated that lenacapavir could be mass-produced for up to $93 per person per year, potentially falling to about $40 per person per year 'if voluntary licences are in place and competition between generic suppliers substantially improves.'
'Voluntary licensing and multiple suppliers are required to achieve these low prices,' the researchers wrote in the study abstract. 'This mechanism is already in place for other antiretrovirals.'
Lenacapavir is the latest HIV prevention shot to receive FDA approval. Apretude, made by GSK's ViiV Healthcare, was the first injectable pre-exposure prophylaxis medication to receive approval in the US in 2021.
The hope is that PrEP tools could lead to a total halt to new HIV infections in future generations, Baeten said.
'Every one of us would like nothing more than to end this epidemic, and that's what really solid prevention can do for us – that coupled with testing and treatment,' he said.
'I want this next generation to think about HIV as something that they can end in their lifetime, end in their generation. And I want their next generation to be one where they've never had to think about HIV at all,' he said. 'We've got this amazing opportune moment right now as a world to think about where we can be in the future. We can be a world without HIV.'
The new FDA approval comes as the Trump administration has cut back funding for HIV-related research grants, HIV prevention and surveillance programs through the US Centers for Disease Control and Prevention, and sharply curtailed global HIV efforts.
The administration's 2026 budget proposal includes the elimination of funding for HIV programs, totaling more than $1.5 billion, according to the HIV+Hepatitis Policy Institute.
With the approval of lenacapavir for PrEP, 'now is not the time to pull the rug out from under HIV prevention,' Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, said in an email.
'The obliteration of CDC HIV prevention and surveillance programs is an absurd proposal that will just increase HIV infections and health costs down the road,' he said. 'We urgently call on Congress to reject these cuts in order to ensure that states and community-based organizations have the resources to prevent HIV, which is still a serious infectious disease and results in about 32,000 new cases each year.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
2 hours ago
- Boston Globe
Anne Merriman, ‘mother of palliative care' in Uganda, dies at 90
For Dr. Merriman, a former nun who would go on to expand palliative care in the developing world -- introducing a replicable, culturally flexible model of hospice to Africa, treating nearly 40,000 patients and training some 10,000 medical professionals across 37 countries on the continent -- that small innovation was, she later wrote, 'a game changer.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Dr. Merriman died May 18 at her home in Kampala, Uganda. She was 90. The cause was respiratory failure, her cousin Chris Merriman said. Advertisement Although hospice centers already existed in Africa when Anne Merriman began working in Uganda in the early 1990s, she envisioned an affordable model of hospice that could be adapted to various developing countries. At the time, the AIDS crisis was at its peak. About 30% of the population of Uganda was HIV positive, and the cancer rate, as a result, was climbing. Average life expectancy was 38 years. The country had recently emerged from a violent dictatorship and a protracted guerrilla war. Advertisement But Dr. Merriman and Mbaraka Fazal, a Kenyan nurse she had met while working in Nairobi, had promising conversations with Uganda's health minister, James Makumbi, and were confident that it would be safe to make the country their home base -- and that they could convince the government of the importance of importing powdered morphine. So in 1992, Dr. Merriman founded Hospice Africa, with the idea of spreading palliative care across the continent. A year later, she started Hospice Africa Uganda, to introduce her model to the country. Initially, it was a shoestring operation. Working out of a small two-bedroom house in Kampala, Dr. Merriman and Fazal mixed morphine powder in buckets with water boiled on the kitchen stove. There was no office equipment, which made writing grants impossible. At one point, their total funding amounted to 19 Ugandan shillings -- less than two American pennies at the time. To make matters worse, local doctors were reluctant to refer their patients, out of fear of enabling opioid addiction or because they equated the analgesic with euthanasia. The first hospice patients -- most of them young women with cancer -- were referred late and often died within weeks. And the nurses who visited patients in remote locations were not able to administer morphine without a doctor's prescription, which meant longer waiting times. But Dr. Merriman pressed on. Driving a donated white Land Rover, she rumbled down bumpy roads to visit hospice patients. Cheerful and well turned out, she wore vibrant kitenge dresses, her hair done and her nails painted for meetings with donors. But while she had a gentle bedside manner, she could be steely, especially in meetings with doctors and government officials. Advertisement Early on, she wrote in a 2010 memoir, her relationship with the country's health ministry became 'as frosty as it can get in a tropical climate' because of the government's lack of support for her work. But eventually things began to improve. Patients in hospice care were no longer in pain, and word began to spread. Medical students that Dr. Merriman had trained became practicing doctors, and they helped shift attitudes. And in 2004, Dr. Merriman finally persuaded the health ministry to allow certain nurses to prescribe morphine. Within five years, Hospice Africa Uganda had three sites in the country. By 2000, Hospice Africa had expanded its training sessions to Tanzania. Today, through its Institute of Hospice and Palliative Care in Africa, Hospice Africa offers degrees in palliative care. Dr. Merriman, who became known as Uganda's 'mother of palliative care,' reflected on her early days in Uganda and the importance of persistence in an interview with The New York Times in 2017. 'You need someone to shout and scream and keep it going,' she said. Anne Merriman was born May 13, 1935, in Liverpool, England, one of four children of Thomas Merriman, the headmaster of a Catholic primary school, and Josephine (Dunne) Merriman, who ran the home and volunteered with Catholic charities. Along with various medical papers, Dr. Merriman published a handbook on geriatric medical practices in 1989 and two memoirs, 'Audacity to Love' (2010) and 'That's How the Light Got In' (2023), written with Autumn Fielding-Monson. Advertisement Dr. Merriman left no immediate survivors. Despite her accomplishments and awards -- she was appointed a Member of the Order of the British Empire in 2003 and received Ireland's Presidential Distinguished Service Award in 2013 -- Dr. Merriman remained loyal to her working-class background. She made a point of avoiding the funerals of famous Ugandans, and was critical of the way the rich were prioritized for medical treatment, not just in Uganda, but around the world. During her final days, she was as attentive to her appearance as ever, and she specified the outfit she wanted to wear to her own funeral: a purple kitenge dress with a bright yellow pattern. Stitched at the center was a map of Africa. This article originally appeared in
Forbes
3 hours ago
- Forbes
U.S. Retreat From Global Vaccine Effort Is A Gift To Diseases, Experts Warn
LONDON, ENGLAND - MAY 19: The Palace of Westminster lit up by Global Citizen in a striking call to ... More action: Renew UK funding for Gavi, the Vaccine Alliance on May 19, 2025 in London, England. (Photo byfor Global Citizen) A decade of protection. That's what Elizabeth Khayumbi was seeking for her six-month-old daughter, Jaisley, on a recent trip to a local public health clinic near Nairobi, Kenya. 'I know immunisation protects her, as I too was protected,' Khayumbi recently told Gavi, the Vaccine Alliance. Over the past twenty-five years, Gavi has helped immunize more than 1.1 billion children just like Jaisley. Working across 78 low-income countries, the organization has prevented nearly 19 million deaths from diseases like pneumonia, diarrhea and measles while creating stronger health systems to help combat other viruses like HIV. Last week, Gavi held its sixth fundraising replenishment, securing $9 billion in pledges—$2.9 billion short of its goal, but more than expected given the turbulent year for global health, especially for multilateral institutions. Portugal increased its contribution by 54%. Indonesia, a country that once received Gavi funding became its newest donor, showing that progress is possible. And the European Commission, Australia and Spain all increased their pledges. But there was one noticeable absence from the donor list: The United States. In a video that was released by the Department of Health and Human Services, Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, announced that the U.S. would not pledge any money to Gavi, saying the organization had 'ignored the science' around vaccine safety. It was a move that doctors described as stunning and calamitous. The U.S. was an original donor to Gavi in 2001 and a rapid retreat from the organization could jeopardize thousands, if not millions, of children's lives. A World With More Deaths And Diseases If you want to see Gavi's impact, just look at a country like Kenya. In 1989, only 44% of Kenyan children were vaccinated. By 2023, that number had risen to over 93%. The organization followed a simple recipe: As Gavi raised more money, it purchased and distributed more life-saving vaccines. As a result, more children were vaccinated against devastating viruses, and more were lives saved. Between 2000 and 2023, Kenya's child mortality rate plummeted from 96 deaths per 1,000 live births to 40 deaths per 1,000 live births. Yes, Gavi invested a lot of money in Kenya, nearly $1 billion, but the Kenyan government also increased its domestic health resources, too. Thanks to their collective efforts, well over one million child deaths were averted. Without U.S. assistance, Gavi will have to make some tough decisions. The organization may have to reduce the number of vaccines it offers or curb the number of countries it helps. Roughly 13% of the organization's budget comes from American taxpayers. Absent U.S. generosity, as many as 75 million fewer children will be vaccinated and an additional one million children could die. Kennedy's announcement, which aligns with President Trump's 'America First' rhetoric, may have also given other countries permission to step back from the world's most vulnerable. The United Kingdom, historically Gavi's top donor, issued a pledge that constituted a 40% cut in real terms from the last commitment made under conservative Prime Minister Boris Johnson. 'Many thousands of children who could have lived will instead die – it's hugely disappointing to see the UK government backsliding rather than driving progress on global poverty,' Dr. Sandy Douglas, a senior vaccinologist at Oxford University's Jenner Institute, told the Guardian. Gavi directly supports vaccination campaigns against roughly 20 diseases ranging from Ebola to malaria. Fewer resources could cause more diseases and infections. Experts fear this could trigger health setbacks for both low-income countries and for Western ones, too, as viruses and diseases do not require passports. Children with less access to vaccines are more likely to contract opportunistic infections that are prevalent among immunocompromised individuals living with viruses like HIV. And a pullback in health system strengthening and capacity building could lead to fewer maternal and newborn health services and higher mother-to-child transmission rates. Who Will Step Up? When countries like the U.S. and U.K. step back, the world does not stand still. Others, like China, tend to step forward. The country's Belt and Road Initiative is well documented. But less has been written about China's efforts to leverage vaccine diplomacy. During the Covid-19 pandemic, China donated hundreds of millions of vaccines to Africa, the Asia-Pacific and Latin America. To date, some Chinese vaccines companies have shunned Gavi-backed markets. However, as Chinese biotechnology companies develop drugs at a faster, cheaper clip than the U.S., they may well be positioned to fill the vacuum. On a hopeful note, Gavi announced new private sector partnerships worth over $149 million to strengthen digital and supply chains. Zipline and Gavi will continue scaling up their vaccine drone-based delivery efforts across Ghana, Côte d'Ivoire, Kenya, and Nigeria. Integrate Health and partners are aiming to further vaccine equity across Guinea and West Africa. And the UPS Foundation committed to helping improve supply chain networks to better deliver vaccines to children in low-income countries. While experts caution there is no substitute for public sector leadership, private sector innovation and expertise can be transformative. What's Next? Following Secretary Kennedy's announcements, advocacy organizations, including the U.S. Global Leadership Coalition underscored the bipartisan nature of America's longstanding support for Gavi and the need for Congress to have the ultimate say. The plea's came as the House and Senate continue the appropriations process that is expected to culminate before the start of the fiscal year on October 1st. In the meantime, Gavi will plow ahead with its essential work. The $9 billion haul of mostly new pledges helps put the organization another step closer to supporting its goal of vaccinating 500 million children from preventable disease and averting between 8 and 9 million future deaths. 'In a very, very dire moment for global health… this is far better than I hoped it would be,' Sania Nishtar, Gavi's Chief Executive, told Reuters. 'But we have to be mindful that if we fall short… there will be lives we are unable to save.'
Yahoo
5 hours ago
- Yahoo
Chronic but not powerless, why your estate plan deserves a seat at the doctor's office
Juggling modern families, demanding careers, shifting politics, doctors' appointments, insurance paperwork, and copays, and everything society throws at us is already a full-time job. Add a chronic condition — like HIV, cancer, multiple sclerosis, or anything that requires ongoing care — and the balancing act becomes something closer to running the gauntlet. It's a lot. And most people don't get it, especially when your condition is invisible. Or stigmatized. Or both. But here's the truth I've learned from working with clients living with chronic illness: The strongest among us don't just "push through." They take control — not just of their health, but of their financial and estate plans. Because the minute life gets complicated, the cost of not planning skyrockets. I've worked with people who've beaten cancer, who live with HIV, juggle therapy appointments and their kids' soccer schedule, all while trying to make sense of their financial goals and dreams. What they have in common isn't just resilience. It's that quiet, sobering moment when they realize: "I need a plan." That moment doesn't happen in every financial advisor's or lawyer's office. Sometimes it hits when a hospital intake form asks, "Do you have a healthcare power of attorney?" Or when someone close to them ends up in a medical crisis with no documents and no clarity. That's when the gravity sinks in: chronic illness doesn't wait for your financial life to be in order. And here's the thing most financial professionals won't say out loud: if you're living with a chronic condition, you can't afford not to plan. Not out of fear, but out of self-respect, love for the people in your life, and power over your own story. Let's start with the part everyone dreads: estate planning. Most people avoid it because it feels like preparing for death. But if you're living with a chronic condition, it's not about dying — it's about protecting your autonomy while you're alive. If your health situation could ever leave you unable to speak for yourself, you need documents that do the talking: Healthcare Power of Attorney: Choose someone you trust (really trust) to make medical decisions on your behalf. Living Will or Advance Directive: Spell out your wishes clearly. Whether it's aggressive treatment or comfort-focused care, this is where your voice lives if you can't speak. HIPAA Authorization: Make sure the right people — especially your partner or chosen family — can access your medical information. Durable Financial Power of Attorney: Someone has to pay the rent and manage your finances if you're in the hospital. Choose wisely. (No offense to your cousin with 13 credit cards and a sneaker reselling habit.) Revocable Living Trust: If you own assets — especially if you're unmarried or estranged from family — this helps ensure your belongings go where you want them to, without court interference. For many in the LGBTQ+ community, chosen family plays a bigger role than blood relatives. But without legal documentation, the system doesn't care who actually showed up for you when it mattered. That's why these documents aren't just "recommended." They're essential. And emotionally? This work can be heavy. For those who have faced rejection from family or institutions, it can resurface painful memories. But it's also one of the most potent acts of self-advocacy you can make. This is about saying: This is who I trust. This is who I love. This is who gets a say. This isn't about doomsday prepping. It's about giving yourself options, control, and flexibility — so your health doesn't dictate your financial future more than it has to. Emergency Funds & Cash Flow Even with insurance, chronic conditions come with unpredictable costs, including copays, travel expenses, and lost income due to time off work. Plan to have: 6–12 months of essential expenses saved Short- and long-term disability coverage (through work or individually) A clear understanding of what your insurance does — and doesn't — cover This isn't paranoia. It's confidence. Insurance (Yes, It's Still Worth Talking About) Most people think life insurance is obvious, but disability insurance is also critical if you rely on your income, and most of us do. But if you're managing a chronic condition, you may face exclusions or outright denials. That's frustrating, but not a dead end. There are still pathways to protecting your family: Group disability coverage through your employer or professional associations may not require medical underwriting. Employer-sponsored life insurance — often guaranteed issue and a great base layer. Life Insurance – many carriers now offer coverage for people living with conditions such as HIV, with recent advancements in treatment. Survivorship policies if you're partnered and one partner is uninsurable alone. Leaning on your partner's benefits, primarily if they work for an inclusive employer that allows domestic partner enrollment, even if not legally married. One HR form could mean access to coverage you wouldn't qualify for on your own. Rethinking Retirement Chronic illness can shift your timeline. Maybe you want to retire early. Perhaps you need more liquidity. Maybe you want the flexibility to work part-time at 50 and focus on advocacy, art, or your own damn peace. Traditional retirement accounts still matter and serve as the foundation. But if you're living with a chronic condition, you might want more flexibility than a standard 401(k) offers. That's where diversification comes in. Think beyond just one type of account. Many of my clients benefit from having a mix of Roth, taxable brokerage accounts, and yes, even the trusty 401(k). The goal is to create options. Because life doesn't always follow a textbook timeline, and your money shouldn't be stuck in one either. For individuals managing chronic conditions, the Health Savings Account (HSA) is the real MVP — or, to be honest, the GOAT. If you qualify for one, an HSA is more than just a savings account. It's a triple-threat: money goes in tax-deductible, grows tax-free, and comes out tax-free when used for medical expenses. It's like having a backstage pass to cover the healthcare costs you already know are on the way. And here's the bonus: after age 65, you can even use it for non-medical expenses without penalty. That flexibility makes it one of the most powerful tools in your financial toolkit, especially if healthcare will always be a line item in your budget. Many clients I work with want to give back to the communities and causes that have helped them, including HIV research, mental health access, LGBTQ+ rights, hospice care, and housing justice. That legacy can also be part of your financial plan. Name a nonprofit as a beneficiary on a life insurance policy, IRA, or 401(k) Use a donor-advised fund to give strategically during your lifetime Include charitable bequests in your will or trust This isn't just about reducing taxes. It's about using your resources to reflect your values. To say: This mattered to me. And I want it to continue. Planning = Peace Here's what I've seen over and over again: once the plan is in place, people breathe differently. There's a lightness. A quiet confidence. A sense of relief that your care, your finances, and your legacy won't be dictated by courts, chaos, or people who don't actually know you. If you're living with a chronic condition, you deserve more than just medical care. You deserve a plan that sees the whole you — your relationships, your resilience, and your right to decide what comes next. So go ahead. Schedule the meeting. Sign the documents. Set the plan in motion. Then? Rest. Enjoy what makes you happy. Travel without "what-ifs." Live with confidence. Because now — finally — you have a plan. Voices is dedicated to featuring a wide range of inspiring personal stories and impactful opinions from the LGBTQ+ community and its allies. Visit to learn more about submission guidelines. Views expressed in Voices stories are those of the guest writers, columnists, and editors, and do not directly represent the views of The Advocate or our parent company, equalpride. This article originally appeared on Advocate: Chronic but not powerless, why your estate plan deserves a seat at the doctor's office
